Dual inhibition of independent cell survival pathways as a new approach for targeting leukemic stem cells [ 2012 - 2014 ]

Research Grant

Researchers: Dr Mark Guthridge (Principal investigator) ,  A/Pr Andrew Wei ,  A/Pr Paul Ekert

Brief description While most leukemia patients initially respond well to chemotherapy, >60% die because the disease returns as a result of the survival of leukaemia cells following treatment. We have shown that targetting two enzymes, PI3K and Cdk9, with a drug called PIK75 potently and specifically kills leukemia cells by blocking their survival. We now seek to examine the therapeutic potential of our discovery with a view toward developing new targetted therapies in the future.

Funding Amount $AUD 562,742.09

Funding Scheme Project Grants

Notes Standard Project Grant